- $1.36tn
- $1.40tn
- $65.18bn
Eli Lilly’s $1.4 trln valuation is heavy with hope
Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion (updated)
Brief: Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly
Deals of the day-Mergers and acquisitions
Lilly signs oncology research deal with Stipple Bio worth up to $5.9 billion
Deals of the day-Mergers and acquisitions
Brief: Calytrix Bio Enters An Agreement To Be Acquired By Lilly
Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet (updated)
Lilly to buy Calytrix Bio for $1.5 billion
DNA drug developer Seawolf launches with $100 million funding, Sanofi deal
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
Brief: Eli Lilly Phase 2 Data Showed Eloratzp Delivered Weight Loss Of Up To Average Of 54.1 Lbs (23.3%) At 48 Weeks In Adults With Obesity, Type 2 Diabetes
Lilly says its obesity drugs helped patients lose weight in clinical trials
CVS says GLP-1s save money when priced below $350 per month
Brief: EMA's CHMP Recommends Extensions Of Indication For Bexsero & Talzenna
Mapping the Market: Eli Lilly shares ready to rally again
U.S. STOCKS ON THE MOVE-Super Micro Computer, EPR Properties, Global Payments
Corrected: Health Canada warns after bacteria found in unauthorized peptides
U.S. STOCKS ON THE MOVE-Southern Company, Diamondback Energy, Keurig Dr Pepper